End-stage renal disease (ESRD) is a risk after kidney donation. We sought, in a large cohort of kidney donors, to determine the causes of donor ESRD, the interval from donation to ESRD, the role of the donor/recipient relationship, and the trajectory of the estimated GFR (eGFR) from donation to ESRD. 
| INTRODUC TI ON
The initial living donor kidney transplants were done with the knowledge that individuals born with 1 kidney could lead a normal life. 1 The assumption was that this would be true for living kidney donors as well. Numerous studies have now confirmed that living kidney donors, as compared with the general population, are not at increased risk for developing any disease long-term. [2] [3] [4] [5] [6] [7] [8] However, 2 recent studies comparing living kidney donors with healthy selected controls did find an increased risk of end-stage renal disease (ESRD) among donors. 9, 10 In the first study, from
Norway, of 1901 kidney donors who donated between 1963 and 2007, 9 (0.47%) subsequently developed ESRD; all had donated to a relative. 9 In the second study, from the United States, of 96 217 kidney donors who donated between April 1, 1994, and November 30, 2011, a total of 99 (0.1%) subsequently developed ESRD; of those 99 donors, 83 (84%) had donated to a relative. 10 Of note, even nondonors who have a relative with ESRD are at increased risk for developing ESRD. [11] [12] [13] [14] [15] [16] [17] [18] How living kidney donors develop ESRD is a key question. Is it due to new-onset disease that would likely have affected both kidneys?
Or is it due to a steady fall in the glomerular filtration rate (GFR) that can occur with aging? And most important, can the rate of developing ESRD after living kidney donation be lowered?
In that recent study from Norway, immunologic disease was the cause of ESRD in 7 (78%) of the 9 donors with ESRD, and type 2 diabetes mellitus (DM) in the other 2 (22%). 9 In the United States, the 2 most common causes of ESRD after donation are DM and hypertension. 10, 19, 20 However, donors who themselves were subsequently listed for a kidney transplant at a younger age were more likely to have their ESRD attributed to focal segmental glomerulosclerosis (FSGS) or hypertension; in contrast, those donors listed at an older age were more likely to have their ESRD attributed to hypertension or DM. 19, 20 In the only study of serial creatinine levels in living kidney donors who developed ESRD (n = 8), Kido et al reported that levels were relatively stable until the onset of new disease. 21 The University of Minnesota has a longstanding living kidney donor program. To date, of 4362 donors, 39 have developed ESRD.
In this report, we describe the causes of their ESRD, the time from donation to ESRD, and the trajectory of the estimated GFR (eGFR)
prior to ESRD development.
| MATERIAL S & ME THODS

| Study population
Our longstanding study of long-term living kidney donor outcomes is approved by the University of Minnesota institutional review board (IRB HSC# 0301M39762). Our population and follow-up protocols have been described in detail. 3, 22 Cumulative incidence of ESRD considering death as a competing risk was estimated using product-limit estimators, and 95% pointwise confidence intervals for the cumulative incidence were estimated using bootstrap resampling.
| Study cohort and analyses
For the current study of donors who developed ESRD, we analyzed their age at donation and the interval from donation to ESRD; the cause of their ESRD; the donor/recipient relationship; and the cause of the recipient's ESRD. To calculate the eGFR, we used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 24 We have previously shown that the CKD-EPI equation is more precise than the MDRD study equation in living kidney donors who underwent GFR measurement with iohexol. 25 Over the last 2 decades, as our donor follow-up effort intensified, there have been more frequent postdonation serum creatinine level measurements (and therefore more eGFR determinations).
All analyses were performed using SAS Version 9. 
| RE SULTS
Of the 4362 individuals undergoing living donor nephrectomy at our center from January 1963 through December 2015, ESRD status was ascertained in 4030 (92%). Those donors for whom we were unable to ascertain ESRD status (n = 332) were more likely to be male, younger at donation, nonwhite, related to the recipient, and smokers with known ESRD status (n = 2423) ( Table 2) . Donors with ESRD came from an earlier era (P < .0001) and were more likely to be male (P = .002) and to be a smoker (P = .05). However, age at donation and being related to their recipient were no longer significantly different between these 2 cohorts.
| Cumulative incidence of ESRD
The 
| Causes and timing of ESRD
Of the 39 donors with ESRD, 25 had an attributed cause (Table 3) .
Of these 25 donors, 12 (48%) had DM and/or hypertension as their cause of ESRD. However, only 3 donors had undergone native kidney biopsy; diagnoses were hemolytic uremic syndrome (HUS) (n = 1), immunotactoid glomerulonephritis (n = 1), and Wegener's granulomatosis (n = 1). Figure 2 shows the relationships between ESRD diagnosis, age at ESRD diagnosis, age at donation, and interval from donation to ESRD. Overall, regardless of age at donation, the majority of ESRD occurred after age 50; DM and hypertension were more frequent in those donors. And the majority of ESRD that occurred late postdonation was due to DM and hypertension. Of the 25, only 2 had a disease (renal cell cancer) that would have affected 1 kidney.
| Donor/recipient relationship
Of the 39 donors with ESRD, 38 (97%) were related to their recipient, of these 38, a total of 35 (90%) were first-degree relatives ( Table 2 ). The cause of donor and recipient ESRD in relation to interval between donation and donor ESRD is shown in 
| Postdonation trajectory of eGFR in donors developing ESRD
For the 22 donors with sufficient eGFR values to portray slope, their eGFR trajectory by age at donation is shown in Figure 3 ; by cause of ESRD in TA A third possibility regarding the pathogenesis of ESRD postdonation is that ESRD is the result of GFR loss with nephrectomy, followed years later by new-onset disease. It would not be surprising that, similar to the general population, some donors ultimately develop new-onset kidney disease and ESRD. Most new-onset kidney diseases would have affected both kidneys 9, 10, 19 ; it is unknown whether donors-who have a lower GFR as a result of nephrectomy-progress to ESRD more rapidly than if they still had 2 kidneys.
| D ISCUSS I ON
As noted earlier, in the only previous study of serial creatinine levels in living donors who developed ESRD (n = 8), Kido et al reported that levels were relatively stable until the development of new disease. 21 Like Kido et al, we found that new-onset disease was followed by a change in slope of eGFR versus time (Figures 3 and 4) . Our study provides additional data that donor eGFR is relatively stable until the development of new disease-either a disease of the In our series, DM was the cause in 2 donors, and DM plus hypertension in 4 (Table 3) . We previously reported on the outcome of donors in our population who developed DM postdonation. 37 At the time of the analysis, 309 donors had developed DM (7.7% of our donor population) at a median age of 56 years, and a median of 18 years after donation. There was no difference in deterioration of renal function in our DM population compared to reports of renal function in microalbuminuric diabetics with 2 kidneys. 38 We also compared renal function in the DM group with that of matched donors not developing DM.
F I G U R E 2 Causes of donor ESRD, by 4 variables: (A) age at ESRD, (B) years postdonation, (C) age at donation, and ESRD, (D) interval
Prior to the development of DM, there was no difference between groups in the annual eGFR change. Similarly, there was no difference between groups in annual eGFR after development of DM. In contrast, those developing DM and also developing hypertension and/or proteinuria within 5 years of DM had a 1 ml/min/1.73 m 2 decline in annual eGFR, no different than that seen in those with 2 kidneys.
The estimated cumulative incidence of ESRD in our series and 34 (20-59) at 20 years. 39 Both studies found about a 50% lower 15-year cumulative incidence than that reported by Muzaale et al in a cohort with maximum follow-up of 15 years (median 7.6 years), 10 suggesting that longer follow-up will be necessary to provide a more precise estimate of ESRD risk.
Understanding the causes of ESRD postdonation is vital for developing criteria for accepting potential donors, for counseling them pre-and postdonation, and for providing long-term donor care. It is unlikely that new-onset immunologic disease can be prevented;
ESRD might ultimately develop in the absence of nephrectomy. But [40] [41] [42] However, given the current organ shortage, limiting living donation to middle-aged or older donors is unrealistic.
In our series, of the 39 donors who developed ESRD, 38 (97.4%)
were related to their recipient; that percentage is significantly higher than the 78.7% related to their recipient in the group not developing ESRD (Table 1) . But, again, all of our donors developing ESRD donated before 2000. When comparing them to donors without ESRD at our center before 2000, there was no significant difference in the proportion who were related to their recipient. Determining whether any increased risk of ESRD after donation only applies to those donating to a relative has important implications for donor counseling.
Unrelated donation was uncommon before the mid-1980s. 43 The preponderance of ESRD in those donating to a relative might be because early in the history of transplantation, unrelated donation was rare;
furthermore, the interval between donation and ESRD is typically long (median 30 years in our series). Most unrelated donors destined to develop ESRD might not yet have had time to reach that stage.
If that is the explanation, all donors might be at equal risk of ESRD.
Alternatively, the preponderance of ESRD in those donating to a relative might be because the risk of ESRD is increased in those related to an individual with ESRD [11] [12] [13] [14] [15] [16] [17] [18] ; if so, unrelated donors (who have no ESRD in their families) may not be at increased risk. 39 An additional calculator, using data from 7 general population cohort studies, was developed by Grams et al to show the projected risk of developing ESRD in the absence of kidney donation. 44 Each of the tools is limited to information in the particular dataset used ( are vastly more common and potentially amenable to intervention (Table 5 ).
There are limitations to our analyses. First, our population is mostly white/non-Hispanic; the incidence of ESRD is higher in blacks and in Hispanics so nephrectomy alone may well have a greater impact in these 2 populations, mainly because their baseline risk of ESRD is higher than in whites. Second, we have ascertained ESRD status in 92% of donors; there may be additional cases in the other 8%. Third, although we did provide a larger number of serial eGFR determinations in donors with ESRD than has been reported previously, the total number of donors in our series with ESRD is still small. Fourth, our pre-1990 donor follow-up was less intense than our post-1990 follow-up, resulting in long periods during that pre-1990 era between early postdonation eGFR determinations and the first late postdonation eGFR determination.
Finally, as noted earlier, most cases lack histologic confirmation of ESRD cause.
In summary, the majority of ESRD developing after living kidney 
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